Paclitaxel release from single and double-layered poly(DL-lactide-co-glycolide)/poly(L-lactide) film for biodegradable coronary stent application

被引:31
作者
Lao, Luciana Lisa [1 ]
Venkatraman, Subbu S. [1 ]
机构
[1] Nanyang Technol Univ, Sch Mat Sci & Engn, Singapore 639798, Singapore
关键词
paclitaxel; in vitro release; biodegradable stent; poly(DL-lactide-co-glycolide); poly(L-lactide);
D O I
10.1002/jbm.a.31706
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Our laboratory has been developing a completely biodegradable coronary stent which is made of bilayers of biodegradable polyesters. This article presents the preliminary work done to exploit the drug delivery potential of such a polymeric stent. An antiproliferative drug (paclitaxel) was added either only to the top layer or to both layers and the in vitro release profiles were monitored for Lip to 90 days. Within 90 days, the measured paclitaxel release was almost entirely from the P(DL)LGA layer. In general, the release profiles show three distinct stages: (a) extremely slow diffusional release, (b) accelerated diffusion-degradation release, and (c) saturation. Separate degradation studies (water absorption, molecular weight reduction, weight loss, and surface topography) were also conducted to better understand the observed release behavior. (C) 2007 Wiley Periodicals, Inc.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 26 条
[1]   In vitro study of release mechanisms of paclitaxel and rapamycin from drug-incorporated biodegradable stent matrices [J].
Alexis, F ;
Venkatraman, SS ;
Rath, SK ;
Boey, F .
JOURNAL OF CONTROLLED RELEASE, 2004, 98 (01) :67-74
[2]   Regional drug delivery with radiation for the treatment of Ewing's sarcoma - In vitro development of a taxol release system [J].
Attawia, MA ;
Borden, MD ;
Herbert, KM ;
Katti, DS ;
Asrari, F ;
Uhrich, KE ;
Laurencin, CT .
JOURNAL OF CONTROLLED RELEASE, 2001, 71 (02) :193-202
[3]   Biocompatibility aspects of new stent technology [J].
Bertrand, OF ;
Sipehia, R ;
Mongrain, R ;
Rodés, JR ;
Tardif, JC ;
Bilodeau, L ;
Côté, G ;
Bourassa, MG .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (03) :562-571
[4]  
Beyar R, 1996, ISRAEL J MED SCI, V32, P515
[5]   Quality of life in ovarian cancer patients: Comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study [J].
Bezjak, A ;
Tu, DS ;
Bacon, M ;
Osoba, D ;
Zee, B ;
Stuart, G ;
Roy, JA ;
Piccart, M ;
Eisenhauer, E .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (22) :4595-4603
[6]   Synthesis and evaluation of water-soluble paclitaxel prodrugs [J].
Feng, X ;
Yuan, YJ ;
Wu, JC .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (22) :3301-3303
[7]   Local drug delivery via a coronary stent with programmable release pharmacokinetics [J].
Finkelstein, A ;
McClean, D ;
Kar, S ;
Takizawa, K ;
Varghese, K ;
Baek, N ;
Park, K ;
Fishbein, MC ;
Makkar, R ;
Litvack, F ;
Eigler, NL .
CIRCULATION, 2003, 107 (05) :777-784
[8]  
FISHBEIN I, 2000, BIOMATERIALS BIOENGI, P313
[9]   Drug-eluting stents: flashy future or flash-in-the-pan? [J].
Fricker, J .
DRUG DISCOVERY TODAY, 2001, 6 (22) :1135-1137
[10]   Drug-eluting stents for the prevention of restenosis: In quest for the holy grail [J].
Hiatt, BL ;
Ikeno, F ;
Yeung, AC ;
Carter, AJ .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2002, 55 (03) :409-417